The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
- Santen Rolls Out Glaucoma Drug Setaneo in Japan
October 24, 2025
- FDA Again Rejects Mitsubishi Tanabe’s Parkinson’s Drug
October 24, 2025
- Kissei’s Linzagolix Approved for Uterine Fibroids in Taiwan
October 24, 2025
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Takeda, Innovent Ink Oncology Deal for Bispecific, ADC Therapies
October 23, 2025
- Padcev/Keytruda Label Expansion Accepted for US FDA Review
October 23, 2025
- Astellas JV Aims to Bridge “Valley of Death” in Cell Therapy Manufacturing: CEO
October 22, 2025
- Krystal Launches Japan’s First DEB Therapy Vyjuvek Gel
October 22, 2025
- Japanese Drug Makers’ Domestic Sales Inch Up on Shift toward Specialty Areas: Fuji Keizai
October 22, 2025
- Sawai, Asahi Kasei Reach Settlement in Teribone Patent Suit
October 22, 2025
- Sumitomo Pharma Drops Option on FunPep’s FPP003 Peptide
October 22, 2025
- Daiichi Sankyo’s Anti-CDH6 ADC Hits Primary Goal in Global PII
October 22, 2025
- Daiichi Sankyo Unveils Dose-Escalation Data on TA-MUC1-Targeting ADC
October 22, 2025
- Taiho Secures Japan, Asian Rights to Arcus’ HIF-2α Inhibitor Casdatifan
October 21, 2025
- Santen Nabs Distribution Rights to Beovu, Lucentis in South Korea
October 21, 2025
- Chugai, Rani Therapeutics Strike Deal on Oral Antibody Drug
October 21, 2025
- Chugai to File Tecentriq for Adjuvant Bladder Cancer Use in 2026 after Positive Data
October 21, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…